| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 10 | 2020 | 77 | 3.070 |
Why?
|
| Bacteremia | 7 | 2023 | 65 | 2.970 |
Why?
|
| Anti-Bacterial Agents | 20 | 2023 | 324 | 2.940 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2020 | 33 | 2.340 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2023 | 80 | 1.760 |
Why?
|
| Staphylococcus | 2 | 2023 | 10 | 1.660 |
Why?
|
| Methicillin Resistance | 5 | 2023 | 22 | 1.540 |
Why?
|
| Staphylococcus aureus | 8 | 2023 | 53 | 1.500 |
Why?
|
| Bacteriological Techniques | 9 | 2018 | 16 | 1.470 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2020 | 35 | 1.430 |
Why?
|
| Bacterial Proteins | 5 | 2022 | 90 | 1.160 |
Why?
|
| Humans | 60 | 2023 | 32114 | 1.150 |
Why?
|
| Bacteria | 5 | 2018 | 48 | 1.090 |
Why?
|
| beta-Lactamases | 3 | 2022 | 13 | 1.060 |
Why?
|
| Pneumocystis carinii | 2 | 2020 | 6 | 1.030 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2022 | 10 | 0.980 |
Why?
|
| Gonorrhea | 2 | 2020 | 12 | 0.890 |
Why?
|
| Cross Infection | 4 | 2019 | 55 | 0.890 |
Why?
|
| BK Virus | 1 | 2022 | 6 | 0.860 |
Why?
|
| Klebsiella pneumoniae | 2 | 2020 | 14 | 0.860 |
Why?
|
| Polyomavirus Infections | 1 | 2022 | 21 | 0.850 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 6 | 0.840 |
Why?
|
| Influenza, Human | 3 | 2019 | 122 | 0.830 |
Why?
|
| Diagnostic Errors | 3 | 2012 | 43 | 0.820 |
Why?
|
| Penicillin-Binding Proteins | 2 | 2020 | 3 | 0.820 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 94 | 0.810 |
Why?
|
| Reagins | 1 | 2022 | 3 | 0.810 |
Why?
|
| Syphilis | 1 | 2022 | 10 | 0.800 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2020 | 8 | 0.760 |
Why?
|
| Pseudomonas Infections | 1 | 2020 | 14 | 0.750 |
Why?
|
| Drug Contamination | 2 | 2018 | 6 | 0.720 |
Why?
|
| Azithromycin | 1 | 2020 | 15 | 0.710 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 517 | 0.710 |
Why?
|
| beta-Lactam Resistance | 1 | 2020 | 2 | 0.700 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 31 | 0.700 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 59 | 0.690 |
Why?
|
| Blood Platelets | 4 | 2009 | 39 | 0.690 |
Why?
|
| Communicable Diseases | 1 | 2019 | 20 | 0.680 |
Why?
|
| Immunocompromised Host | 5 | 2020 | 51 | 0.680 |
Why?
|
| Syringes | 1 | 2018 | 5 | 0.650 |
Why?
|
| Antifungal Agents | 5 | 2018 | 40 | 0.650 |
Why?
|
| Anesthetics | 1 | 2018 | 18 | 0.640 |
Why?
|
| Operating Rooms | 1 | 2018 | 35 | 0.630 |
Why?
|
| Strongyloidiasis | 1 | 2017 | 3 | 0.610 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 18 | 0.600 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2020 | 47 | 0.560 |
Why?
|
| Gram-Negative Bacteria | 2 | 2013 | 8 | 0.490 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2013 | 14 | 0.490 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2020 | 11 | 0.470 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2021 | 24 | 0.450 |
Why?
|
| Platelet Transfusion | 4 | 2009 | 16 | 0.430 |
Why?
|
| Shiga Toxin | 1 | 2012 | 2 | 0.430 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2012 | 3 | 0.430 |
Why?
|
| Chromatography, Affinity | 1 | 2012 | 15 | 0.430 |
Why?
|
| Feces | 1 | 2012 | 38 | 0.430 |
Why?
|
| Daptomycin | 1 | 2012 | 3 | 0.430 |
Why?
|
| Enterococcus faecalis | 1 | 2012 | 12 | 0.430 |
Why?
|
| Enterococcus faecium | 1 | 2012 | 5 | 0.430 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 39 | 0.410 |
Why?
|
| Fatal Outcome | 6 | 2018 | 83 | 0.410 |
Why?
|
| Carbapenems | 2 | 2022 | 7 | 0.400 |
Why?
|
| Mycoses | 2 | 2011 | 20 | 0.400 |
Why?
|
| Fungi | 1 | 2011 | 7 | 0.380 |
Why?
|
| Laboratories, Hospital | 1 | 2010 | 3 | 0.360 |
Why?
|
| Bacterial Infections | 3 | 2006 | 51 | 0.360 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 16 | 0.360 |
Why?
|
| Mycobacterium Infections | 1 | 2010 | 1 | 0.360 |
Why?
|
| Corynebacterium Infections | 1 | 2010 | 3 | 0.360 |
Why?
|
| Mycobacterium | 1 | 2010 | 3 | 0.360 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 10 | 0.350 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 9 | 0.340 |
Why?
|
| Bone Marrow Diseases | 1 | 2009 | 2 | 0.340 |
Why?
|
| Pneumocystis Infections | 1 | 2009 | 2 | 0.340 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2009 | 4 | 0.330 |
Why?
|
| United States | 8 | 2020 | 3976 | 0.330 |
Why?
|
| Male | 16 | 2020 | 19217 | 0.330 |
Why?
|
| Bone Marrow | 1 | 2009 | 70 | 0.320 |
Why?
|
| Time Factors | 6 | 2018 | 2151 | 0.310 |
Why?
|
| Amphotericin B | 3 | 2018 | 12 | 0.310 |
Why?
|
| Lung Diseases, Fungal | 2 | 2018 | 7 | 0.310 |
Why?
|
| Drug Resistance, Microbial | 3 | 2022 | 14 | 0.300 |
Why?
|
| Polymerase Chain Reaction | 2 | 2021 | 198 | 0.300 |
Why?
|
| Adult | 13 | 2020 | 9380 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 2004 | 73 | 0.290 |
Why?
|
| Influenza A virus | 2 | 2019 | 22 | 0.290 |
Why?
|
| Drug Resistance, Fungal | 2 | 2003 | 3 | 0.280 |
Why?
|
| Fluconazole | 2 | 2003 | 8 | 0.270 |
Why?
|
| Child, Preschool | 4 | 2020 | 1270 | 0.260 |
Why?
|
| Female | 18 | 2020 | 20015 | 0.260 |
Why?
|
| Erythromycin | 2 | 2002 | 7 | 0.260 |
Why?
|
| Sepsis | 2 | 2004 | 161 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 582 | 0.250 |
Why?
|
| Blood Component Transfusion | 1 | 2004 | 10 | 0.250 |
Why?
|
| Streptococcus pyogenes | 2 | 2003 | 16 | 0.240 |
Why?
|
| DNA, Viral | 2 | 2022 | 54 | 0.240 |
Why?
|
| Seasons | 2 | 2019 | 91 | 0.240 |
Why?
|
| Streptococcal Infections | 2 | 2003 | 22 | 0.240 |
Why?
|
| Middle Aged | 11 | 2019 | 11839 | 0.230 |
Why?
|
| Laboratories | 1 | 2023 | 15 | 0.230 |
Why?
|
| Length of Stay | 2 | 2023 | 314 | 0.230 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 100 | 0.220 |
Why?
|
| Candidiasis | 1 | 2003 | 5 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2003 | 9 | 0.220 |
Why?
|
| Candida albicans | 1 | 2003 | 12 | 0.220 |
Why?
|
| Esophageal Diseases | 1 | 2003 | 7 | 0.220 |
Why?
|
| Mitosporic Fungi | 1 | 2003 | 2 | 0.220 |
Why?
|
| Cephalosporins | 1 | 2023 | 9 | 0.220 |
Why?
|
| Antibodies, Bacterial | 2 | 2022 | 32 | 0.220 |
Why?
|
| Viral Load | 1 | 2022 | 70 | 0.210 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 21 | 0.210 |
Why?
|
| Pneumonia | 2 | 2020 | 68 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2002 | 40 | 0.210 |
Why?
|
| Cell Culture Techniques | 2 | 2014 | 173 | 0.200 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2022 | 4 | 0.200 |
Why?
|
| Treponema pallidum | 1 | 2022 | 7 | 0.200 |
Why?
|
| Animals | 4 | 2020 | 7542 | 0.200 |
Why?
|
| Immunoassay | 1 | 2021 | 16 | 0.190 |
Why?
|
| Carrier State | 1 | 2020 | 23 | 0.190 |
Why?
|
| Bacterial Typing Techniques | 2 | 2014 | 17 | 0.190 |
Why?
|
| Membrane Proteins | 1 | 2002 | 256 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 58 | 0.180 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2020 | 3 | 0.180 |
Why?
|
| Cefixime | 1 | 2020 | 4 | 0.180 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 6 | 0.180 |
Why?
|
| Osteomyelitis | 1 | 2020 | 22 | 0.180 |
Why?
|
| Pharynx | 1 | 2020 | 14 | 0.180 |
Why?
|
| Penicillins | 1 | 2020 | 11 | 0.180 |
Why?
|
| Tetracycline | 1 | 2020 | 13 | 0.180 |
Why?
|
| Ceftriaxone | 1 | 2020 | 14 | 0.180 |
Why?
|
| Arthritis, Infectious | 1 | 2020 | 24 | 0.180 |
Why?
|
| Virology | 1 | 2020 | 1 | 0.180 |
Why?
|
| Mycological Typing Techniques | 1 | 2020 | 1 | 0.180 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2020 | 13 | 0.180 |
Why?
|
| Oxacillin | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hospitals | 1 | 2020 | 102 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 6 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 48 | 0.170 |
Why?
|
| Enterobacteriaceae | 2 | 2017 | 11 | 0.170 |
Why?
|
| Health Facilities | 1 | 2019 | 10 | 0.170 |
Why?
|
| Clindamycin | 3 | 2007 | 22 | 0.170 |
Why?
|
| North Carolina | 3 | 2020 | 1538 | 0.170 |
Why?
|
| Drug Packaging | 1 | 2018 | 6 | 0.160 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 91 | 0.160 |
Why?
|
| Blood Preservation | 3 | 2009 | 11 | 0.160 |
Why?
|
| Child | 6 | 2016 | 2442 | 0.160 |
Why?
|
| Ascomycota | 1 | 2018 | 4 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 517 | 0.150 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 3 | 0.150 |
Why?
|
| Piperacillin | 1 | 2017 | 6 | 0.150 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 6 | 0.150 |
Why?
|
| Cryptococcosis | 1 | 2017 | 5 | 0.150 |
Why?
|
| Ivermectin | 1 | 2017 | 9 | 0.150 |
Why?
|
| Pharmacists | 1 | 2018 | 20 | 0.150 |
Why?
|
| Plateletpheresis | 2 | 2009 | 3 | 0.150 |
Why?
|
| Physicians | 1 | 2019 | 159 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2020 | 898 | 0.150 |
Why?
|
| Colony Count, Microbial | 3 | 2010 | 18 | 0.140 |
Why?
|
| Culture Media | 2 | 2009 | 47 | 0.140 |
Why?
|
| Aged | 5 | 2019 | 10314 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 876 | 0.130 |
Why?
|
| Sphingomonas | 1 | 2015 | 3 | 0.130 |
Why?
|
| Meningitis | 1 | 2015 | 9 | 0.130 |
Why?
|
| Virulence | 2 | 2007 | 22 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 408 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 47 | 0.130 |
Why?
|
| Community-Acquired Infections | 2 | 2007 | 32 | 0.130 |
Why?
|
| Adolescent | 5 | 2016 | 3568 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 4 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2014 | 2 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2015 | 49 | 0.120 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2014 | 10 | 0.120 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
| Young Adult | 4 | 2016 | 2665 | 0.120 |
Why?
|
| Chile | 3 | 2006 | 7 | 0.120 |
Why?
|
| Electrophoresis | 1 | 2014 | 8 | 0.120 |
Why?
|
| Multiple Organ Failure | 2 | 2014 | 10 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 91 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 88 | 0.110 |
Why?
|
| Computational Biology | 1 | 2014 | 91 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 50 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2014 | 177 | 0.110 |
Why?
|
| Hematuria | 1 | 2012 | 11 | 0.110 |
Why?
|
| Lactobacillus | 1 | 2012 | 14 | 0.110 |
Why?
|
| Urinalysis | 1 | 2012 | 27 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 251 | 0.110 |
Why?
|
| Gentamicins | 1 | 2012 | 5 | 0.100 |
Why?
|
| Peritonitis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Mupirocin | 1 | 2012 | 3 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 10 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2012 | 15 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 37 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2012 | 26 | 0.100 |
Why?
|
| Hyphae | 1 | 2011 | 1 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 17 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 16 | 0.090 |
Why?
|
| Cushing Syndrome | 1 | 2010 | 1 | 0.090 |
Why?
|
| Nocardia asteroides | 1 | 2010 | 2 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2010 | 13 | 0.090 |
Why?
|
| Rifampin | 1 | 2010 | 8 | 0.090 |
Why?
|
| Staphylococcus epidermidis | 1 | 2010 | 6 | 0.090 |
Why?
|
| Ventriculostomy | 1 | 2010 | 11 | 0.090 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2010 | 7 | 0.090 |
Why?
|
| Minocycline | 1 | 2010 | 11 | 0.090 |
Why?
|
| Urine | 1 | 2011 | 65 | 0.090 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2010 | 18 | 0.090 |
Why?
|
| Education, Continuing | 1 | 2010 | 7 | 0.090 |
Why?
|
| Mass Screening | 1 | 2012 | 263 | 0.090 |
Why?
|
| Organizational Innovation | 1 | 2010 | 31 | 0.090 |
Why?
|
| Calorimetry | 1 | 2009 | 4 | 0.090 |
Why?
|
| Blood | 1 | 2009 | 14 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2009 | 16 | 0.090 |
Why?
|
| Equipment Contamination | 1 | 2009 | 12 | 0.090 |
Why?
|
| Geotrichosis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Geotrichum | 1 | 2009 | 1 | 0.090 |
Why?
|
| Echinocandins | 1 | 2009 | 6 | 0.090 |
Why?
|
| Lipopeptides | 1 | 2009 | 6 | 0.090 |
Why?
|
| Neutropenia | 1 | 2009 | 29 | 0.090 |
Why?
|
| Phenotype | 2 | 2002 | 632 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 27 | 0.090 |
Why?
|
| Bacterial Capsules | 1 | 2009 | 4 | 0.080 |
Why?
|
| Microscopy, Atomic Force | 1 | 2009 | 5 | 0.080 |
Why?
|
| Bacterial Adhesion | 1 | 2009 | 6 | 0.080 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2008 | 3 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2008 | 10 | 0.080 |
Why?
|
| Spleen | 1 | 2009 | 87 | 0.080 |
Why?
|
| Ustilaginales | 1 | 2008 | 3 | 0.080 |
Why?
|
| Fungemia | 1 | 2008 | 3 | 0.080 |
Why?
|
| Short Bowel Syndrome | 1 | 2008 | 12 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2008 | 108 | 0.080 |
Why?
|
| Skin | 1 | 2009 | 211 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 62 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 20 | 0.070 |
Why?
|
| Vancomycin Resistance | 1 | 2007 | 8 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 34 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 246 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 414 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2006 | 31 | 0.070 |
Why?
|
| Disease Reservoirs | 1 | 2006 | 2 | 0.070 |
Why?
|
| Bartonella henselae | 1 | 2006 | 2 | 0.070 |
Why?
|
| Serotyping | 2 | 2003 | 19 | 0.070 |
Why?
|
| Quality Control | 1 | 2006 | 44 | 0.070 |
Why?
|
| Cats | 1 | 2006 | 108 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2003 | 11 | 0.060 |
Why?
|
| Blood Donors | 1 | 2004 | 14 | 0.060 |
Why?
|
| Contact Tracing | 2 | 2020 | 9 | 0.060 |
Why?
|
| Clostridium difficile | 1 | 2004 | 12 | 0.060 |
Why?
|
| Intestinal Diseases | 1 | 2004 | 16 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 2004 | 9 | 0.060 |
Why?
|
| Methicillin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Sterilization | 1 | 2003 | 2 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2003 | 48 | 0.060 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 9 | 0.060 |
Why?
|
| Candidiasis, Oral | 1 | 2003 | 10 | 0.060 |
Why?
|
| Cryptococcus neoformans | 1 | 2003 | 2 | 0.060 |
Why?
|
| Candida | 1 | 2003 | 7 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 32 | 0.050 |
Why?
|
| Risk Factors | 2 | 2018 | 3880 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2002 | 5 | 0.050 |
Why?
|
| Phenazines | 1 | 2002 | 1 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gentian Violet | 1 | 2002 | 3 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2002 | 20 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2014 | 2283 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 1062 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 19 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 122 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 263 | 0.040 |
Why?
|
| Alternaria | 1 | 2018 | 1 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2018 | 18 | 0.040 |
Why?
|
| Knee | 1 | 2018 | 33 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 53 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 186 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2018 | 129 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 184 | 0.030 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 43 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 3990 | 0.030 |
Why?
|
| Cryoglobulins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2015 | 35 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 765 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 672 | 0.030 |
Why?
|
| Reagent Strips | 1 | 2012 | 4 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 29 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2012 | 6 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 474 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 483 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 3510 | 0.020 |
Why?
|
| Nocardia Infections | 1 | 2010 | 2 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2010 | 19 | 0.020 |
Why?
|
| Prosthesis-Related Infections | 1 | 2010 | 22 | 0.020 |
Why?
|
| Agar | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
| Color | 1 | 2009 | 13 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 32 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1328 | 0.020 |
Why?
|
| Water | 1 | 2009 | 56 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 125 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1817 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 392 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2006 | 8 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 10 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 297 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 44 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3306 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2003 | 10 | 0.010 |
Why?
|
| Empyema, Pleural | 1 | 2003 | 7 | 0.010 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 17 | 0.010 |
Why?
|
| Shock, Septic | 1 | 2003 | 25 | 0.010 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 32 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 78 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 288 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 733 | 0.010 |
Why?
|